Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122


SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I.

Rajecki M, Sarparanta M, Hakkarainen T, Tenhunen M, Diaconu I, Kuhmonen V, Kairemo K, Kanerva A, Airaksinen AJ, Hemminki A.

PLoS One. 2012;7(3):e32871. doi: 10.1371/journal.pone.0032871. Epub 2012 Mar 7.


Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer.

Barton KN, Stricker H, Elshaikh MA, Pegg J, Cheng J, Zhang Y, Karvelis KC, Lu M, Movsas B, Freytag SO.

Mol Ther. 2011 Jul;19(7):1353-9. doi: 10.1038/mt.2011.89. Epub 2011 May 17.


Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.

Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A.

Clin Cancer Res. 2009 Sep 1;15(17):5396-403. doi: 10.1158/1078-0432.CCR-08-2571. Epub 2009 Aug 25.


Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus.

Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mittra A, Gonen M, Zanzonico PB, Fong Y, Szalay AA.

J Transl Med. 2011 Mar 31;9:36. doi: 10.1186/1479-5876-9-36.


Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.

Oneal MJ, Trujillo MA, Davydova J, McDonough S, Yamamoto M, Morris JC 3rd.

Hum Gene Ther. 2012 Sep;23(9):951-9. doi: 10.1089/hum.2012.047. Epub 2012 Aug 22.


Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter.

Peerlinck I, Merron A, Baril P, Conchon S, Martin-Duque P, Hindorf C, Burnet J, Quintanilla M, Hingorani M, Iggo R, Lemoine NR, Harrington K, Vassaux G.

Clin Cancer Res. 2009 Nov 1;15(21):6595-601. doi: 10.1158/1078-0432.CCR-09-0262. Epub 2009 Oct 27.


Effect of increased viral replication and infectivity enhancement on radioiodide uptake and oncolytic activity of adenovirus vectors expressing the sodium iodide symporter.

Oneal MJ, Trujillo MA, Davydova J, McDonough S, Yamamoto M, Morris JC 3rd.

Cancer Gene Ther. 2013 Mar;20(3):195-200. doi: 10.1038/cgt.2013.4. Epub 2013 Feb 15.


Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter.

Haddad D, Chen CH, Carlin S, Silberhumer G, Chen NG, Zhang Q, Longo V, Carpenter SG, Mittra A, Carson J, Au J, Gonen M, Zanzonico PB, Szalay AA, Fong Y.

PLoS One. 2012;7(8):e41647. doi: 10.1371/journal.pone.0041647. Epub 2012 Aug 17.


Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.

Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC 3rd, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL.

Cancer Gene Ther. 2012 Sep;19(9):659-65. doi: 10.1038/cgt.2012.47. Epub 2012 Jul 13.


Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells.

Li W, Tan J, Wang P, Wu P.

Cancer Biother Radiopharm. 2011 Aug;26(4):443-51. doi: 10.1089/cbr.2010.0908. Epub 2011 Jul 28.


A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.

Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC.

Cancer Gene Ther. 2012 Dec;19(12):839-44. doi: 10.1038/cgt.2012.68. Epub 2012 Oct 5.


Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter.

Gao XF, Zhou T, Chen GH, Xu CL, Ding YL, Sun YH.

Asian J Androl. 2014 Jan-Feb;16(1):120-3. doi: 10.4103/1008-682X.122354.


Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

J Nucl Med. 2013 Aug;54(8):1450-7. doi: 10.2967/jnumed.112.115493. Epub 2013 Jul 10.


Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model.

Ahn SJ, Jeon YH, Lee YJ, Lee YL, Lee SW, Ahn BC, Ha JH, Lee J.

Cancer Gene Ther. 2010 Jul;17(7):492-500. doi: 10.1038/cgt.2010.3. Epub 2010 Feb 26.


A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC.

Gene Ther. 2010 Nov;17(11):1325-32. doi: 10.1038/gt.2010.63. Epub 2010 Apr 29.


Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter.

Kim SH, Chung HK, Kang JH, Kim KI, Jeon YH, Jin YN, Yun CO, Chung JK.

Hum Gene Ther. 2008 Sep;19(9):951-7. doi: 10.1089/hgt.2008.030.


SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene.

Merron A, Peerlinck I, Martin-Duque P, Burnet J, Quintanilla M, Mather S, Hingorani M, Harrington K, Iggo R, Vassaux G.

Gene Ther. 2007 Dec;14(24):1731-8. Epub 2007 Oct 25.


Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.

Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC.

Cancer Res. 2003 Nov 15;63(22):7840-4. Erratum in: Cancer Res. 2004 Feb 15;64(4):1559. Cancer Res. 2003 Dec 15;63(24):9057.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk